14 research outputs found
Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation
No full textHigh-dose cyclophosphamide followed by autologous haematopoietic stem cell transplantation (HDC-AHSCT) is a treatment option for aggressive and refractory multiple sclerosis (MS). Natalizumab is a monoclonal antibody approved for relapsing-remitting (RR) MS unresponsive to immunomodulating drugs. Nothing is known about the use of natalizumab in patients after HDC-AHSCT. We describe five female RR-MS patients with incomplete response to HDC-AHSCT. Natalizumab was then administered with abolition of both MRI and clinical activity. No severe adverse events, in particular opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML), were observed. Our results suggest that the use of natalizumab in aggressive RR-MS after HDC-AHSCT could be effective and safe. The very long-term risk of adverse events due to sequential aggressive immunosuppression has to be established
Comparing two methods of sequential fractionation in the study of copper compounds in Haplic chernozem under model experimental conditions
No full textNew approaches to studying heavy metals in soils by X-ray absorption spectroscopy (XANES)) and extractive fractionation
No full textNatalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation
No full textPhytomass change in natural phytocenosis as an indicator of technogenic pollution of soils with heavy metals
No full textMethods of sequential extraction of heavy metals from soils: New approaches and the mineralogical control (a review)
No full text
A powerful tool for assessing distribution and fate of potentially toxic metals (PTMs) in soils: integration of laser ablation spectrometry (LA-ICP-MS) on thin sections with soil micromorphology and geochemistry
No full text
